Zhu, Z., Chen, H., Feng, C., Chen, L., Ma, C., Liu, Z., Qu, Z., Bartlett, D. L., Lu, B., Li, K., Guo, Z. S.

Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy

24 de July de 2025 by Zhu, Z., Chen, H., Feng, C., Chen, L., Ma, C., Liu, Z., Qu, Z., Bartlett, D. L., Lu, B., Li, K., Guo, Z. S.

Background
Oncolytic virus (OV)-mediated immunotherapy has been shown limited efficacy. Small molecule inhibitors specific to the KRASG12C driver oncoprotein have recently been developed for cancer treatment. The combination of a potent OV with a KRAS…